Eli Lilly faces market headwinds, slowing growth, and rising competition. Discover why now might be the time for LLY ...

Eli Lilly’s first quarter saw rapid revenue growth, but the market responded negatively due to profit shortfalls and emerging ...

Vital chemotherapy drugs used around the world have failed quality tests, putting cancer patients in more than 100 countries ...

CVS shares rose 4.7% at 3:43 p.m. in New York on Thursday, while Lilly fell 11%. Novo shares gained 2.1% in Copenhagen. Novo and Lilly have been locked in a fierce competition to dominate the ...

Eli Lilly on Thursday downplayed CVS Health's decision to drop the company's obesity drug Zepbound from some lists of medicines it covers for reimbursement, but shares of the drugmaker still fell ...

Summary. Eli Lilly and Company's stock fell over 11% after CVS Caremark excluded Lilly’s obesity drug Zepbound from its standard commercial formularies starting July 1, 2025.

Eli Lilly will ship the two highest doses of its popular weight-loss drug Zepbound to cash-paying customers on its website ...

Several major U.S. health insurers announce they will voluntarily speed up and simplify the prior authorization process.

CVS Health opts for Wegovy and Saxenda on its formulary; ... Patients taking Zepbound will be able to switch to Wegovy if the Lilly drug is excluded from their coverage, Whitrap said.

(Reuters) -Eli Lilly on Thursday downplayed CVS Health's decision to drop the company's obesity drug Zepbound from some lists of medicines it covers for reimbursement, but shares of the drugmaker ...